• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies

  • Print
  • Share
  • E-mail
-

Post-Approval Studies

  • In January 2005, the oversight responsibility of the Post-Approval Studies Program was transferred to the Division of Epidemiology (DEPI) of the Office of Surveillance and Biometrics (OSB)/Center for Devices and Radiological Health (CDRH).
  • The CDRH Post-Approval Studies Program encompasses design, tracking, oversight, and review responsibilities for studies mandated as a condition of approval of a premarket approval (PMA) application, protocol development product (PDP) application, or humanitarian device exemption (HDE) application. The program helps ensure that well-designed post-approval studies (PAS) are conducted effectively and efficiently and in the least burdensome manner.
  • CDRH has established an automated, internal tracking system that efficiently identifies the reporting status of active PAS studies ordered since January 1, 2005 based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH's effort to ensure that all PAS commitments are fulfilled in a timely manner.
  • In addition, CDRH launched this publicly available webpage to keep all stakeholders informed of the progress of each PAS. The webpage displays general information regarding each PAS, as well as the overall study status (based on protocol-driven timelines and the adequacy of the data) and the applicant's reporting status for each submission due.

Links

Contact Information

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD
20993-0002

Phone: (301) 796-6134
Fax: (301) 847-8140
julie.unger@fda.hhs.gov

Show All Studies
Export to ExcelExport to Excel
General
Application Number P070012
Most Recent Protocol Version Approved 10/23/2007
Study Name EMERGE
Study Status Terminated
Study Progress Reason Device not marketed
General Study Protocol Parameters
Study Design Prospective Cohort Study
Study involve follow-up of premarket cohort (Y/N) No
Data Source Sponsor Registry
Comparison Group Historical Control
Analysis Type Descriptive
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description The primary objective of the EMERGE study is to evaluate the safety of the Exponent   show the rest ...
Study Population Description This device is indicated for use, in conjunction with a Medtronic Vascular embolic protection system,   show the rest ...
Sample Size 1500 patients, 50 sites
Data Collection The protocol defined primary endpoint for each phase of the trial was the cumulative incidence   show the rest ...
Followup Visits and Length of Followup All patients will be followed to 30 days, the first 500 patients will be followed for 365 days.
Final Study Results
Actual Number of Patients Enrolled 0
Actual Number of Sites Enrolled 0
Patient Followup Rate Not applicable
Final Safety Findings None, study was never started.
Study Strengths and Weaknesses None, study was not conducted.
Recommendations for Labeling Changes No labeling changes recommended since study was not conducted.


Show All Studies

-
-